清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

医学 不利影响 中性粒细胞减少症 内科学 临床终点 慢性淋巴细胞白血病 耐火材料(行星科学) 胃肠病学 布鲁顿酪氨酸激酶 白细胞减少症 皮疹 化疗 临床试验 白血病 酪氨酸激酶 物理 受体 天体生物学
作者
Anthony R. Mato,Nirav N. Shah,Wojciech Jurczak,Chan Y. Cheah,John M. Pagel,Jennifer A. Woyach,Bita Fakhri,Toby A. Eyre,Nicole Lamanna,Manish R. Patel,Alvaro J. Alencar,Ewa Lech‐Marańda,William G. Wierda,Catherine C. Coombs,James N. Gerson,Paolo Ghia,Steven Le Gouill,David Lewis,Suchitra Sundaram,Jonathon B. Cohen
出处
期刊:The Lancet [Elsevier BV]
卷期号:397 (10277): 892-901 被引量:469
标识
DOI:10.1016/s0140-6736(21)00224-5
摘要

Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance. We evaluated the safety and efficacy of pirtobrutinib (working name; formerly known as LOXO-305), a highly selective, reversible BTK inhibitor, in these patients.Patients with previously treated B-cell malignancies were enrolled in a first-in-human, multicentre, open-label, phase 1/2 trial of the BTK inhibitor pirtobrutinib. The primary endpoint was the maximum tolerated dose (phase 1) and overall response rate (ORR; phase 2). This trial is registered with ClinicalTrials.gov, NCT03740529.323 patients were treated with pirtobrutinib across seven dose levels (25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg once per day) with linear dose-proportional exposures. No dose-limiting toxicities were observed and the maximum tolerated dose was not reached. The recommended phase 2 dose was 200 mg daily. Adverse events in at least 10% of 323 patients were fatigue (65 [20%]), diarrhoea (55 [17%]), and contusion (42 [13%]). The most common adverse event of grade 3 or higher was neutropenia (32 [10%]). There was no correlation between pirtobrutinib exposure and the frequency of grade 3 treatment-related adverse events. Grade 3 atrial fibrillation or flutter was not observed, and grade 3 haemorrhage was observed in one patient in the setting of mechanical trauma. Five (1%) patients discontinued treatment due to a treatment-related adverse event. In 121 efficacy evaluable patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) treated with a previous covalent BTK inhibitor (median previous lines of treatment 4), the ORR with pirtobrutinib was 62% (95% CI 53-71). The ORR was similar in CLL patients with previous covalent BTK inhibitor resistance (53 [67%] of 79), covalent BTK inhibitor intolerance (22 [52%] of 42), BTK C481-mutant (17 [71%] of 24) and BTK wild-type (43 [66%] of 65) disease. In 52 efficacy evaluable patients with mantle cell lymphoma (MCL) previously treated with covalent BTK inhibitors, the ORR was 52% (95% CI 38-66). Of 117 patients with CLL, SLL, or MCL who responded, all but eight remain progression-free to date.Pirtobrutinib was safe and active in multiple B-cell malignancies, including patients previously treated with covalent BTK inhibitors. Pirtobrutinib might address a growing unmet need for alternative therapies for these patients.Loxo Oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
霸气的慕山完成签到,获得积分10
1秒前
幸福海之完成签到,获得积分10
4秒前
syvshc的应助被科研通管家采纳,获得10
7秒前
栀盎完成签到 ,获得积分10
8秒前
慧子完成签到 ,获得积分10
24秒前
稳重的从寒完成签到,获得积分10
34秒前
Haibrar完成签到 ,获得积分10
38秒前
云峤完成签到 ,获得积分10
39秒前
xBiomeOS发布了新的文献求助30
41秒前
含蓄的雪冥完成签到,获得积分10
1分钟前
大方的仙人掌完成签到,获得积分10
1分钟前
蝎子莱莱xth完成签到,获得积分0
1分钟前
yoqalux完成签到 ,获得积分10
1分钟前
氢锂钠钾铷铯钫完成签到,获得积分10
1分钟前
Square完成签到,获得积分10
1分钟前
糟糕的翅膀完成签到,获得积分0
1分钟前
搜集达人的应助被12彡采纳,获得10
1分钟前
白奕发布了新的文献求助10
1分钟前
xiaotan000完成签到,获得积分10
1分钟前
1分钟前
12彡发布了新的文献求助10
1分钟前
1分钟前
科研通AI6.3的应助被白奕采纳,获得10
1分钟前
xBiomeOS发布了新的文献求助30
1分钟前
1分钟前
蓝梦诗音完成签到 ,获得积分10
2分钟前
ValerieLI发布了新的文献求助10
2分钟前
2分钟前
syvshc的应助被科研通管家采纳,获得10
2分钟前
从容的嫣娆完成签到,获得积分10
2分钟前
靓丽花瓣完成签到,获得积分10
2分钟前
无极微光的应助被Lanyiyang采纳,获得20
2分钟前
霸气的高丽完成签到,获得积分10
2分钟前
2分钟前
2分钟前
柠檬水完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185453
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834496
捐赠科研通 7783067
什么是DOI,文献DOI怎么找? 3434570
关于科研通互助平台的介绍 2558912
邀请新用户注册赠送积分活动 2481326